Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
AEON Biopharma, Inc. (AEON)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: AEON (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7.2
1 Year Target Price $7.2
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -64.19% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 9.20M USD | Price to earnings Ratio - | 1Y Target Price 7.2 |
Price to earnings Ratio - | 1Y Target Price 7.2 | ||
Volume (30-day avg) 1 | Beta 0.71 | 52 Weeks Range 0.38 - 115.57 | Updated Date 09/16/2025 |
52 Weeks Range 0.38 - 115.57 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -13.91 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -129.01% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE 1.16 | Enterprise Value 17079153 | Price to Sales(TTM) 97.16 |
Enterprise Value 17079153 | Price to Sales(TTM) 97.16 | ||
Enterprise Value to Revenue 201.68 | Enterprise Value to EBITDA -5.89 | Shares Outstanding 11643800 | Shares Floating 8196294 |
Shares Outstanding 11643800 | Shares Floating 8196294 | ||
Percent Insiders 23.38 | Percent Institutions 12.04 |
Upturn AI SWOT
AEON Biopharma, Inc.
Company Overview
History and Background
AEON Biopharma, Inc. is a biopharmaceutical company focused on developing a botulinum toxin neurotoxin complex for a variety of indications, including chronic migraine and cervical dystonia. Founded with the goal of advancing therapeutic options in these areas.
Core Business Areas
- Therapeutic Development: Focused on developing and commercializing botulinum toxin products for neurological and pain-related conditions.
Leadership and Structure
Key leaders include the CEO and CFO. The organizational structure supports drug development and regulatory approval processes.
Top Products and Market Share
Key Offerings
- ABP-450: AEON Biopharma's lead product candidate, ABP-450, is a botulinum toxin type A injection being developed for the treatment of chronic migraine and cervical dystonia. Market share is currently 0% as the drug is still undergoing clinical trials. Major competitors include Botox (Allergan/AbbVie), Dysport (Ipsen), and Xeomin (Merz).
Market Dynamics
Industry Overview
The botulinum toxin market is substantial and growing, driven by demand for cosmetic and therapeutic applications. The industry is characterized by established players and increasing competition.
Positioning
AEON Biopharma aims to capture market share by demonstrating superior efficacy or safety compared to existing botulinum toxin products.
Total Addressable Market (TAM)
The global botulinum toxin market is estimated to be several billion USD. AEON Biopharma seeks to establish a significant presence by targeting specific therapeutic indications. The TAM is likely between $5 billion and $10 billion, and AEON Biopharma is positioned to capture a portion of this through its specific drug programs.
Upturn SWOT Analysis
Strengths
- Novel botulinum toxin formulation
- Experienced management team
- Targeting specific therapeutic indications
- Strong intellectual property portfolio
Weaknesses
- Reliance on successful clinical trials
- Lack of established commercial infrastructure
- Dependence on funding
- No current product revenue
Opportunities
- Expanding therapeutic indications
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results
- Increasing awareness of botulinum toxin benefits
Threats
- Competition from established botulinum toxin products
- Regulatory hurdles
- Clinical trial failures
- Adverse events associated with botulinum toxin
Competitors and Market Share
Key Competitors
- ABBV
- IPN
- MRZ
Competitive Landscape
AEON Biopharma faces strong competition from established players with significant market share. Success hinges on differentiating ABP-450 through improved efficacy or safety.
Growth Trajectory and Initiatives
Historical Growth: Growth is tied to clinical trial progress and securing funding.
Future Projections: Future growth is dependent on regulatory approvals and commercialization of ABP-450.
Recent Initiatives: Initiated Phase II and Phase III clinical trials for ABP-450 in various indications, securing funding for clinical development programs.
Summary
AEON Biopharma is a development-stage biopharmaceutical company with potential in the botulinum toxin market. Its success is contingent on the successful development and commercialization of ABP-450. Strong competitors and regulatory challenges pose significant risks. Securing funding and demonstrating clinical superiority are crucial for future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Analyst estimates
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About AEON Biopharma, Inc.
Exchange NYSE MKT | Headquaters Irvine, CA, United States | ||
IPO Launch date 2021-04-12 | President, CEO & Director Mr. Robert Bancroft | ||
Sector Healthcare | Industry Biotechnology | Full time employees 5 | Website https://www.aeonbiopharma.com |
Full time employees 5 | Website https://www.aeonbiopharma.com | ||
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.